Conformal radiotherapy for prostate cancer: An overview;Radiotherapie conformationnelle des cancers de la prostate: Revue generale

Cancer/Radiotherapie

Volumn 3, Issue 5, 1999, Pages 393-406

  Chauvet, B ^a   Oozeer, R ^a   Bey, P ^b   Pontvert, D ^c   Bolla, M ^d  

^a INSTITUT SAINTE CATHERINE   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c INSTITUT CURIE   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

3D treatment planning; Conformal radiation therapy; Prostate cancer

Indexed keywords

CYPROTERONE ACETATE; GONADORELIN DERIVATIVE; GOSERELIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; HUMAN; IMMOBILIZATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; REVIEW; SURVIVAL RATE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; FOLLOW UP; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; QUALITY CONTROL; RADIATION RESPONSE; TIME;

ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY CONTROL; RADIATION DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; TIME FACTORS;

EID: 0033192280     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(00)87977-9     Document Type: Article

References (99)

1. Alasti H, Catton C, Middlemiss N, Ottewell G, Green L, Warde P. Portal imaging for evaluation of daily on-line setup errors and off-line organ motion for radiotherapy of carcinoma of the prostate, [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. Int J Radiat Oncol Biol Phys 1998 ; 42 : 293.
2. Algan Ö, Hanks G, and Shaer A. Localization of the prostatic apex for radiation treatment planning. Int J Radiat Oncol Biol Phys 1995 ; 33 : 925-30.
3. Ames J, Hartz W, Litwin S, Hanks G. The retrograde urethrogram is more accurate than CT in identifying the caudal prostate margin for conformal treatment planning, [abstract]. 35th American Society for Therapeutic Radiology and Oncology Annual Meeting. New Orleans. Int J Radiat Oncol Biol Phys 1993 ; 27 : 137-8.
4. Asbell SO, Martz KL, Shin KH, Sause WT, Doggett RL, Perez CA, et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG n° 77-06: A phase III study for T1bN0M0 and T2N0M0 prostate carcinoma. Int J Radiat Oncol Biol Phys 1998 ; 40 : 69-82.
5. Balter J, Lam K, Sandler H, Littles J, Bree R, Ten Haken, RK. Automated localization of the prostate at the time of treatment using implanted radiopaque markers: Technical feasibility. Int J Radiat Oncol Biol Phys 1995 ; 33 : 1281-6.
6. Balter J, Sandler H, Lam K, Bree R, Lichter A, Ten Haken RK. Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int J Radiat Oncol Biol Phys 1995; 31 : 113-8.
7. Beard CJ, Kijewski P, Bussiere M, Gelman R, GlaDstone D, Shaffer K, et al. Analysis of prostate and seminal vesicle motion: Implications for treatment planning. Int J Radiat Oncol Biol Phys 1996; 34:451-8.
8. Bentel GC, Marks LB, Sherouse GW, Spencer DP, and Anscher MS. The effectiveness of immobilization during prostate irradiation. Int J Radiat Oncol Biol Phys 1995; 31 : 143-8.
9. Bergström P, Löfroth P, And Widmark A. High-precision conformal radiotherapy (HPCRT) of prostate cancer - A new technique for exact positioning of the prostate at the time of treatment. Int J Radiat Oncol Biol Phys 1998; 42 : 305-11.
10. e Congrès national de la société française de radiothérapie oncologique. Cancer, Radiother 1996; 83 : 435-6.
11. Boersma L, van Der Brink M, Bruce A, Shouman T, Gras L, Te Velde A, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998; 41 : 83-92.
12. Bolla M, Cinquin P, Troccaz J, Vassal P, Laieb N, Menguy Y, et al. Procédure de la radiothérapie conformative tridimensionnelle et mise en correspondance des données pré- et per-radiothérapiques. Bull Cancer 1995; 82 Suppl : 586-91.
13. Bolla M, Gonzalez D, Warde P, Dubois J, Mirimanoff R, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337 : 295-300.
14. Bostwick D, Qian J, Bergstralh E, Dundore P, Dugan J, Myers R, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996; 155 : 1361-7.
15. Chauvet B, Jacob T, Davin J, Berger C, Vincent P, and Reboul F. Prostate specific antigen (PSA) : Impact d'un marqueur sérique sur la prise en charge diagnostique et thérapeutique des cancers de prostate. Cancer, Radiother 1996; 83 : 334-44.
16. Chen L.M, LUbich L, Chiru P, Ignacio L, Sweeney P, Chen G.T, et al. Localization of the prostatic apex for radiotherapy planning: A comparison of two techniques. Br J Radiol 1996; 69 : 821-9.
17. Corn B, Hanks G, Schultheiss T, Hunt M, Lee W, Coia L. Conformal treatment of prostate cancer with improved targeting: Superior prostate-specific antigen response compared to standard treatment. Int J Radiat Oncol Biol Phys 1995; 32 : 325-30.
18. Crook J.M, Raymond Y, Salhani D, Yang H, Esche B. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 1995; 37 : 35-42.
19. Dearnaley D, Khoo V, Norman A, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal radiotherapy in prostate cancer: A randomised trial. Lancet 1999; 353 : 267-72.
20. Debras B, Guillonneau B, Bougaran J, Chambon E, Vallancien G. Prognostic significance of seminal vesicle invasion on the radical prostatectomy specimen, rationale for seminal vesicle biopsies. Eur Urol 1998; 33: 271-7.
21. Egan A. and Bostwick D. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: Perineural invasion lacks significance on multivariate analysis. Am J Surg Pathol 1997; 21 : 1496-500.
22. El-Gaayed AA, Bel A, Vijlbrief R, Bartelink H, and Lebesque JV. Time trend of patient setup deviations during pelvic irradiation using electronic portal imaging. Radiother Oncol 1993; 26 : 162-71.
23. Fiorino C, Reni M, Cattaneo G, Bolognesi A, Calandrino R. Comparing 3-4-and 6-fields techniques for conformal irradiation of prostate and seminal vesicles using dose-volume histograms. Radiother Oncol 1997; 44 : 251-7.
24. Fiveash J, Hanks G, Roach III M, Wang S, Vigneault E, McLaughlin P, et al. 3D conformal radiation therapy (DCRT) for high grade prostate cancer: A multi-institutional review, [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. Int J Radiat Oncol Biol Phys 1998; 42 : 143.
25. Orman J.D, Kumar R, Haas G, Montie J, Porter A.T, and Mesina C.F. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: Effects on the volume of normal tissue irradiation. Cancer Invest 1995; 13 : 132-3.
26. 125I implantation. Int J Radiat Oncol Biol Phys 1991; 21 : 537-47.
27. Gallagher M, Breton H, Rostock R, Zero J, Zekoski D, Poyss L, et al. A prospective study of treatment techniques to minimize the volume of pelvic small bowell with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys 1986; 12 : 1565-73.
28. Garcia R, Oozeer R, Le Thanh H, Chauvet B, Toy BJ, Reboul F. Radiothérapie conformationnelle des cancers de prostate : Apport de la contention pelvienne et de nouveaux repères de positionnement. Cancer/Radiother 1997; 1 : 307-13.
29. Hanks G. More on the uro-oncology research group report of radical surgery versus. Radiotherapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1988; 14 : 1053-4.
30. Hanks G, Diamond J, Krall J, Kramer S. A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiat Oncol Biol Phys 1987; 13 : 499-505.
31. Hanks G, Hanlon A, Horwitz E, Pinover W, Schultheiss T. A relationship of local prostate dose and subsequent metastasis with 3D CRT in prostate cancer, [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. Int J Radiat Oncol Biol Phys 1998; 42 : 143.
32. Hanks G, Hanlon A, Schultheiss T, Pinover W, Movsas B, Epstein B, et al. Dose escalation with 3D conformal treatment: Five year outcome, treatment optimization and future directions. Int J Radiat Oncol Biol Phys 1998; 41 : 501-10.
33. Hanks G, Leibel S, Krall J, Kramer S. Patterns of care studies: Dose-response observations for local control of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1985; 11 : 153-7.
34. Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, et al. Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997; 37 : 543-50.
35. Hanley J, Lumley M, Mageras G, Sun J, Zelefsky M, Leibel S, et al. Measurement of patient positioning errors in three-dimensional conformal radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 1997; 37 : 435-44.
36. Jackson A, Zelefsky M, Cowan D, Venkatraman E, Skwarchuk M, Burman C, et al. Rectal bleeding after conformal radiotherapy of prostate cancer and dose volume histograms, [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. Int J Radiat Oncol Biol Phys 1998; 42 : 217.
37. Jamieson T, Sibley G, Zhou S, Maguire P, Light K, Antoine P, et al. Pretreatment dosimetric parameters predict for the risk of proctitis in prostate cancer patients treated with 3-dimensional radiation therapy, [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. Int J Radiat Oncol Biol Phys 1998; 42: 218.
38. Kagawa K, Lee W, Schultheiss T, Hunt M, Shaer A, Hanks G. Initial clinical assessement of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997; 38 : 319-25.
39. Kaplan I, Prestidge B, Bagshaw M, Cox RS. The importance of local control in the treatment of prostatic cancer. J Urol 1992; 147:917-21.
40. Klein E. Radiation therapy versus radical prostatectomy in the PSA era: A urologist's view. Semin Radiat Oncol 1998; 8 : 87-94.
41. Korman H, Watson R, Civantos F, Block N, Soloway M. Radical prostatectomy: Is complete resection of the seminal vesicles really necessary? J Urol 1996; 156 : 1081-3.
42. Lattanzi J, McNeely S, Hanlon A, Das I, Schultheiss T, Hanks G. Daily CT localization for correcting portal errors in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41 : 1079-86.
43. Laverdière J, Gomez J, Cusan L, Suburu E, Diamond P, Lemay M, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37 : 247-52.
44. Lebesque JV, Bruce AM, Kroes AP, Touw A, Shouman RT, van Herk M. Variation in dose-volume histograms and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy. Int J Radiat Oncol Biol Phys 1995; 33 : 1109-19.
45. Lee WR, Hanks GE, Hanlon AL, Schultheiss Te, and Hunt MA. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 1996; 35 : 251-7.
46. Leibel S, Fuks Z, Zelefsky M, Whitmore WJ. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 1994; 28 : 7-16.
47. 198Au implants and external irradiation. Acta Oncol 1995; 34 : 959-64.
48. Lennernäs B, Rikner G, Letocha H, and Nilsson S. External beam radiotherapy of localized prostatic adenocarcinoma. Evaluation of conformal therapy field number and target margins. Acta Oncol 1995; 34: 953-8.
49. Ling C, Burman C, Chui CS, Kutcher GJ, Leibel SA, LoSasso T, et al. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 1996; 35 : 721-30.
50. 7e Congrès national de la société française de radiothérapie oncologique, Paris. Cancer/Radiother 1996; 84 : 435-6.
51. Mesina CF, Sharma R, Rissman LS, Geering L, He T, Forman JD. Comparison of a conformal nonaxial boost with a four-field boost technique in the treatment of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994; 30 : 427-30.
52. Michalsky J, Purdy J, Winter K, Roach M, Vijayakumar S, Sandler H, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. Int J Radiat Oncol Biol Phys 1998; 42 : 142.
53. Mubata C, Bidmead A, Ellingham L, Thompson V, Dearnaley D. Portal imaging protocol for radical dose-escalated radiotherapy treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1998; 40 : 221-31.
54. Neal A.J, Oldham M, Dearnaley D.P. Comparison of treatment techniques for conformal radiotherapy of the prostate using dose-volume histograms and normal tissue complication probabilities. Radiother Oncol 1995; 37 :29-34.
55. Nguyen L, Pollack A, Zagars G. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: Results of a self-assessment questionnaire. Urology 1998; 51 : 991-7.
56. Oesterling J, Chan D, Epstein J, Kimball A, Bruzek D, Rock R, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988; 139 : 766-72.
57. Ohori M, Abbas F, Wheeler T, Kattan M, Scardino P, Lerner S. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol 1999; 161 : 500-4.
58. Ohori M, Scardino P, Lapin S, Seale-Hawkins C, Link J, Wheeler T. The mechanisms and prognostic significance of seminal vesicle involvment by prostate cancer. Am J Surg Pathol 1993; 17: 1252-61.
59. Oozeer R, Chauvet B, Garcia R, Berger C, Félix-Faure C, Reboul F. Évaluation dosimétrique d'une radiothérapie conformationnelle : Le facteur de conformation. Cancer/Radiother 2000 (à paraître).
60. Oozeer R, Chauvet B, Toy B, Berger C, GaRcia R, Felix-Faure C, et al. Définition des contours prostatiques sur coupes tomodensimétriques : Étude des discordances entre radiothérapeutes et entre examens. Cancer/Radiother 1999; 3 : 333-40.
61. Paulson D, Lin G, HinshaW W, Stephani S, and the Uro-Oncology Research Group. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982; 128 : 502-4.
62. Perez C, Pilepich M, Garcia D, Simpson J, Zivnuska F, Hederman M. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: Experience at the Mallinckrodt Institute of radiology. NCI Monogr 1988; 7 : 85-94.
63. Pettaway C. Prognostic markers in clinically localized prostate cancer. Tech Urol 1998; 4 : 35-42.
64. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of radiation therapy oncology group protocol 85-31. J Clin Oncol 1997; 15 : 1013-21.
65. Pilepich M, Winter K, Roach M, Russel A, Sause W, Rubin P, et al. Phase III radiation therapy oncology group trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate, [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. 1998; 42: 177.
66. Pinover W, Hanlon A, Horwitz E, and Hanks G. Defining the appropriate dose for prostate cancer patients with PSA<10ng/ml. [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. Int J Radiat Oncol Biol Phys 1998; 42 : 142.
67. Pollack A. and Zagars G. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 39 : 1011-8.
68. PollAck A, Zagars GK, Starkschall G, CHildress CH, Kopplin S, Boyer AL, et al. Conventional vs. Conformal radiotherapy for prostate cancer: Preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996; 34 : 555-64.
69. Pommier P, Carrie C, Bey P, Beckendorf V, Maingon P, Horiot J, et al. Tolerance of dose escalation with conformal radiotherapy in prostate cancer: Preliminary results of a multicentric study, [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. Int J Radiat Oncol Biol Phys 1998; 42: 310.
70. Rasch C, Barillot I, Remeijer P, Touw A, van Herk M, Lebesque J. Definition of the prostate in CT and MRI: A multi-observer study. Int J Radiat Oncol Biol Phys 1999; 43 : 57-66.
71. Reinstein LE, Xiao-Hong W, Burman CM, Chen Z, Mohan R, Kutcher G, et al. A feasibility study of automated inverse treatment planning for cancer of the prostate. Int J Radiat Oncol Biol Phys 1998; 40 : 207-14.
72. Remeijer P, Rasch C, van Herk M, Lebesque J. A general methodology for analysis of variation in target volume delineation in 3-D. [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. Int J Radiat Oncol Biol Phys 1998; 42: 139.
73. Roach MR, Faillace-Akazawa P, Malfatti C, Holland J, Hricak H. Prostate volumes defined by magnetic resonance imaging and computerized tomography scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1996; 35 : 1011-8.
74. Roach MR, Pickett B, Holland J, Zapotowski K, Marsh D, Tatera B. The role of the uretrogram during simulation for localized prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25 : 299-307.
75. Roeske JC, Forman JD, Mesina CF, He T, Pelizzari CA, Fontenla E, et al. Evaluation of changes in the size and location of the prostate seminal vesicles bladder and rectum during a course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 1995; 33 : 1321-9.
76. Rosenthal S, Roach M, Goldsmith B, Doggett E, Pickett B, Yuo H, et al. Immobilization improves the reproducibility of patient positioning during six-field conformal radiation therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 1993; 27 : 921-6.
77. Sandler H, Bree R, McLaughlin P, Grossman H, and Lichter A. Localization of the prostatic apex for radiation therapy using implanted markers. Int J Radiat Oncol Biol Phys 1993; 27 : 915-9.
78. Sardino P. and Wheeler T. Local control of prostate cancer with radiotherapy: Frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr 1988; 7 : 95-103.
79. Schild S, Buskirk S, Robinow J. Prostate cancer: Retrograde urethrography to improve treatment planing for radiation therapy. Radiology 1991; 181 : 885-7.
80. Skwarchuk M, Jackson A, Zelefsky M, Cowan D, Venkatraman E, Burman C, et al. Analysis of geometric and dosimetric factors that correlate with late rectal bleeding after conformal radiotherapy of prostate cancer, [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. Int J Radiat Oncol Biol Phys 1998; 42 : 218.
81. Smit WG, Helle PA, van Putten WL, Wijnmaalen AJ, Seldenrath Jj, and van Der Werf-Messing BH. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 1990; 18 : 23-9.
82. Song P, Washington M, Vaida F, Hamilton R, Chen G, Vijayakumar S. A comparison of four patient immobilization devices in the treatment of prostate cancer patients with three dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1996; 34 : 213-9.
83. Sweeney P, Vijayakumar S, Sibley G, Salehpour M, Myrianthopoulos L, Rubin S, et al. Comparison of CT-based treatment planning and retrograde urethrography in determining the prostatic apex at simulation. Med Dosim 1993; 18 : 21-8.
84. Tait DM, Nahum A, Meyer L, Law M, Dearneley D, Horwich A, et al. Acute toxicity in pelvic radiotherapy: A randomised trial of conformal versus conventional treatment. Radiother Oncol 1997; 42: 121-36.
85. Ten Haken RK, Perez-Tamayo C, Tesser R, McShan D, Fraas B, Lichter AS. Boost treatment of the prostate using shaped fixed fields. Int J Radiat Oncol Biol Phys 1989; 16 : 193-200.
86. Teshima T, Hanks GE, Hanlon AL, Peter RS, and Schultheiss TE. Rectal bleeding after conformal 3D treatment of prostate cancer: Time to occurrence response to treatment and duration of morbidity. Int J Radiat Oncol Biol Phys 1997; 39 : 77-83.
87. Troccaz J, Menguy Y, Bolla M, Cinquin P, Vassal P, Laieb N, et al. Conformal external radiotherapy of prostatic carcinoma: Requirements and experimental results. Radiother Oncol 1993; 29 : 176-83.
88. Troncoso P, Babaian R, Ro J, Grignon D, von Eschenbach A, Ayala A. Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens. Urology 1989; 34 : 52-6.
89. Valicenti R, Michalsky J, Bosch W, Graham M, Cheng A, Purdy J, et al. Is weekly port filming adequate for verifying patient position in modern radiation therapy? Int J Radiat Oncol Biol Phys 1994; 30:431-8.
90. Vicini F, Ziaja E, Martinez A. Letter to the editor: Regarding Zelefsky et al. IJROBP 41 : 491-500. Int J Radiat Oncol Biol Phys 1999; 43 : 235.
91. Voges G, McNeal J, Redwine E, Freiha F, Stamey T. Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer 1992; 69 : 520-6.
92. Wurzer J, Hanlon A, Horwitz E, Pinover W, and Hanks G. Analysis of bNED control and factors predicting outcome in non-palapable (clinical stage T1c) adenocarcinoma of the prostate treated with 3D conformal external beam radiation therapy. [abstract]. 40th American Society for Therapeutic Radiology and Oncology Annual Meeting. Phoenix. Int J Radiat Oncol Biol Phys 1998; 42 : 144.
93. Yang FE, Chen GT, Ray P, Vaida F, Chiru P, Hamilton RJ, et al. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33 : 1009-17.
94. Zelefsky M, Happersett L, Leibel S, Burman C, Schwartz L, Dicker A, et al. The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1997; 37 : 13-9.
95. Zelefsky M. and Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urology 1997; 49 Suppl : 38-45.
96. Zelefsky M, Leibel S, Burman C, Kutcher G, HArrison A, HapperSett L, et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994; 29: 755-61.
97. Zelefsky M, Leibel S, and Fuks Z. Letter to the editor: Response to Drs Vicini, Ziaja, Martinez. Int J Radiat Oncol Biol Phys 1999; 43 : 235.
98. Zelefsky M, Leibel S, Gaudin P, Kutcher G, Fleshner N, Venkatramen E, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41 : 491-500.
99. Zelefsky M, Leibel S, Kutcher G, and Fuks Z. Three-dimensional conformal radiotherapy and dose escalation: Where do we stand? Semin Radiat Oncol 1998; 8 : 107-14.